Håkansson, Irene http://orcid.org/0000-0002-7497-3521
Tisell, Anders
Cassel, Petra
Blennow, Kaj
Zetterberg, Henrik
Lundberg, Peter
Dahle, Charlotte
Vrethem, Magnus
Ernerudh, Jan
Funding for this research was provided by:
Vetenskapsrådet (K2013-61X-22310-01-4)
Article History
Received: 8 May 2018
Accepted: 4 July 2018
First Online: 18 July 2018
Ethics approval and consent to participate
: The study was approved by The Regional Ethics Committee in Linköping, and written informed consent was obtained from all participants.
: Not applicable
: KB has served as a consultant or at advisory boards for IBL International, Roche Diagnostics, Eli Lilly, Fujirebio Europe, and Novartis. Dr. Blennow is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg. HZ has served at advisory boards of Eli Lilly and Roche Diagnostics and has received travel support from Teva. Dr. Zetterberg is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg. CD has received honoraria for lectures from Biogen, Teva, Genzyme, and Novartis and for advisory boards from Roche, Novartis, and Biogen. MV has received unrestricted research grants from Biogen and Novartis, honoraria for lectures from Biogen and Genzyme and for advisory boards from Roche and Novartis. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.